Table 1. Characterization of the T1D patients.
Patient | Sex | Age, years | Duration of T1D, weeks | Medication* | ICA | GAD | IA-2 |
---|---|---|---|---|---|---|---|
1 | M | 32 | <1 | No | Pos | Pos | Pos |
2 | F | 32 | 12 | No | Neg | Pos | Neg |
3 | F | 31 | <1 | No | Pos | Pos | Pos |
4 | F | 23 | <1 | No | Pos | Neg | ND |
5 | M | 19 | <1 | No | Neg | Neg | Pos |
6 | F | 35 | <1 | No | Pos | Pos | Pos |
7 | F | 33 | 28 | No | Pos | Pos | ND |
F, female; M, male. The presence (Pos), absence (Neg), or no data available (ND) of antibodies to islet cells (ICA), glutamic acid decarboxylase (GAD), and tyrosine phosphatase IA2 (IA-2) are marked. Healthy blood donors, all negative for ICA, GAD, and IA-2, served as sources of control sera.
Insulin was the only medication administered